How gene therapies are changing the Qualified Person role in the EU
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
For emerging and mid-sized biopharma companies, selecting a drug development partner is now a strategic decision that can determine whether…
The pharmaceutical industry is investing heavily in therapies capable of delivering high-potent treatments to diseased cells while limiting damage to…
Traditional approaches to patient-trial matching often rely solely on structured data, leading to inaccurate eligibility lists and missed opportunities to…
Global obesity trials are scaling fast with GLP‑1 therapies, making complete data capture essential to preserve scientific integrity and timelines.…
Radiopharmaceutical therapies are moving from niche innovation to a mainstream oncology option. For supply chains built around stable, mass-produced medicines,…
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in…
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
As oncology therapies mature, post-approval research is essential to supporting regulatory commitments, label expansion, and real-world adoption—often under tight timelines.…
As clinical trials become more digitalised, the data landscape is expanding faster than the processes designed to control it. Electronic…